VERU INC. - COMMON STOCK

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

21 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

01 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru to Present at the Jefferies Healthcare Conference

24 5 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 Second Quarter Financial Results

11 5 2023 05:30:00 提供 Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

04 5 2023 07:30:01 提供 Nasdaq GlobeNewswire

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

03 5 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023

27 4 2023 05:45:00 提供 Nasdaq GlobeNewswire

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

20 4 2023 05:45:00 提供 Nasdaq GlobeNewswire

Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector

19 4 2023 07:30:20 提供 Nasdaq GlobeNewswire

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

11 4 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program

04 4 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

07 3 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS

02 3 2023 15:01:00 提供 Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 First Quarter Financial Results

09 2 2023 05:30:00 提供 Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023

26 1 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

10 1 2023 07:30:00 提供 Nasdaq GlobeNewswire

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

05 12 2022 05:30:00 提供 Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

28 11 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

09 11 2022 19:55:21 提供 Nasdaq GlobeNewswire

Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

24 10 2022 07:30:00 提供 Nasdaq GlobeNewswire